{"filing":{"accession_number":"0001193125-26-400213","cik":"0001671584","ticker":"APVO","company_name":"Aptevo Therapeutics Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"apvo-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/apvo-20260924.htm"},"events":[{"id":34757,"run_id":32002,"accession_number":"0001193125-26-400213","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Aptevo announced progress in optimizing next-generation trispecific candidates for scalable manufacturing and expects to enter IND-enabling studies for lead candidate APVO451 in 1H2027. This is a material operational and development milestone for a clinical-stage biotech company—advancing a lead program toward human testing represents a significant strategic and value-creating event. While not a specific named category, this is clearly an operational/developmental milestone rather than financial, governance, or legal in nature.","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38590,"accession_number":"0001193125-26-400213","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced progress in optimizing next-generation trispecific candidates for scalable manufacturing and expects to enter IND-enabling studies for lead candidate APVO451 in 1H2027. This is a material operational and development milestone for a clinical-stage biotech company—advancing a lead program toward human testing represents a significant strategic and value-creating event. While not a specific named category, this is clearly an operational/developmental milestone rather than financial, governance, or legal in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:04:30.739297+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38590,"accession_number":"0001193125-26-400213","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced progress in optimizing next-generation trispecific candidates for scalable manufacturing and expects to enter IND-enabling studies for lead candidate APVO451 in 1H2027. This is a material operational and development milestone for a clinical-stage biotech company—advancing a lead program toward human testing represents a significant strategic and value-creating event. While not a specific named category, this is clearly an operational/developmental milestone rather than financial, governance, or legal in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:04:30.739297+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-09-24"}]}